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Abstract
Background: Chagas' disease is the major cause of disability secondary to tropical diseases in
young adults from Latin America, and around 20 million people are currently infected by T. cruzi.
Heart failure due to Chagas cardiomyopathy is the main clinical presenation in Colombia. Heart
failure due to Chagas' disease may respond to digoxin, diuretics and vasodilator therapy. Beta-
adrenoreceptor antagonism seems to protect against the increased risk of cardiac arrhythmia and
sudden death due to chronic sympathetic stimulation. The aim of this study is to evaluate the effects
of the selective beta-adrenergic receptor blocker Bisoprolol on cardiovascular mortality, hospital
readmission due to progressive heart failure and functional status in patients with heart failure
secondary to Chagas' cardiomyopathy.
Methods/design: A cohort of 500 T. cruzi seropositive patients (250 per arm) will be selected
from several institutions in Colombia. During the pretreatment period an initial evaluation visit will
be scheduled in which participants will sign consent forms and baseline measurements and tests will
be conducted including blood pressure measurements, twelve-lead ECG and left ventricular
ejection fraction assessment by 2D echocardiography. Quality of life questionnaire will be
performed two weeks apart during baseline examination using the "Minnesota living with heart
failure" questionnaire. A minimum of two 6 minutes corridor walk test once a week over a two-
week period will be performed to measure functional class. During the treatment period patients
will be randomly assigned to receive Bisoprolol or placebo, initially taking a total daily dose of 2.5
mgrs qd. The dose will be increased every two weeks to 5, 7.5 and 10 mgrs qd (maximum
maintenance dose). Follow-up assessment will include clinical check-up, and blood collection for
future measurements of inflammatory reactants and markers. Quality of life measurements will be
obtained at six months. This study will allow us to explore the effect of beta-blockers in chagas'
cardiomyopathy.
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Background
Chagas' disease (CD) is a permanent threat for almost a
quarter of the population of Latin America. Although the
disease has been described in almost all Central and
South America, clinical presentation and epidemiological
characteristics are variable among the different endemic
zones [1,2]. A wide range of prevalence rates has also been
reported suggesting local differences in transmission of
the disease as well as differences in vectors and reservoirs
[3].
Chagas' cardiomyopathy (CCM) represents a serious pub-
lic health problem in most Latin American countries, and
the most recent statistics provided by the World Health
Organization indicate that 100 million persons are
exposed to the disease and approximately 20 million are
currently infected [4]. Interestingly, in addition to the nat-
ural infection foci, an increase in the transmission associ-
ated with blood transfusions has also been noticed. These
statistics are considered an underestimation of the real
rates of infection, most likely due to lack of reports from
highly endemic retired rural communities. In countries in
which the disease is endemic such as Colombia, Vene-
zuela and Brazil, the overall prevalence of infection aver-
ages 10%. However, in highly endemic rural areas rates
have ranged from 25% to 75% [5]. Prevalence of infection
varies widely even between cities and provinces within the
same country because of variations in climate, housing
condition, public health measures, and urbanization. The
actual prevalence of clinical Chagas' disease and the
number of case fatalities are largely unknown, mainly
because case reporting is virtually nonexistent in many
areas in which CD is highly endemic.
Congestive heart failure (CHF) is a late manifestation of
CD that results from structural abnormalities and exten-
sive and irreversible damage to the myocardium. Heart
failure in T. cruzi infected patients usually occurs after age
40 and follows AV block or ventricular aneurysm. How-
ever, when CHF develops in patients less than 30 years old
it is frequently associated with a more aggressive myocar-
ditis and an extremely poor prognosis [1]. The mortality
attributable to CD is related to the severity of the underly-
ing heart disease. Very high mortality is often found in
patients with CHF [2], however, mortality in asympto-
matic seropositive patients varies greatly between geo-
graphic regions, suggesting that other factors may
influence the severity and progression rate of cardiac dis-
ease. It is believed that cardiac damage in CD progresses
slowly but steadily over decades, from subclinical myocar-
ditis to mild segmental abnormalities with conduction
defects, to severe ventricular structural abnormalities, and
finally to overt congestive heart failure and sudden cardiac
death. Besides the poor prognosis of CHF due to Chagas'
disease, it is important to estimate the risk of complica-
tions and death in patient infected with T. cruzi. Unfortu-
nately, few clinical studies have addressed this issue. Most
T. cruzi infected patients have mild or no clinical disease,
however, the percentage of infected people that will
develop detectable cardiac abnormalities is approximately
30 to 40% [3], but only 20% of them will develop symp-
tomatic cardiac involvement [6]. Like CHF from other
causes, CHF due to CD responds to digital, diuretics and
vasodilators therapy [7]. Additionally, some studies have
shown that angiotensin-converting enzyme (ACE) inhibi-
tors improve survival in patients with moderate to severe
CHF due to CD [8]. In spite of its benefits on patients with
non Chagas' disease CHF, there is considerable uncer-
tainty about the potential role of ACE inhibitors in
patients with CHF due to Chagas' disease. Captopril, and
ACE inhibitors, has been shown to reduce neurohormo-
nal activation and non-lethal arrhymias in a small
number of patients with Chagas' heart failure [8,9].
Another intervention currently included in the manage-
ment of CHF patients is the use of b blockers. Observa-
tional studies [10] as well as clinical trials [11,12] have
shown that b-blockers reduce morbidity and mortality in
CHF patients. The effects of b-blockers on CHF patients
are being studied in large scale clinical trials [13-19].
Apparently, the cardiac sympathetic hyperstimulation
that initially helps to preserve ventricular function in CHF
patients, later on, results in an increased risk of cardiac
arrhythmia and sudden death [20] b-adrenoreceptor
antagonism seems to protect against the deleterious
effects of chronic sympathetic stimulation [21]. Moreover,
b-blockers reduce heart rate, improve myocardial ener-
getic balance and lead to a less negative force-frequency
relationship. These effects contribute to the benefits of b-
blocker therapy in CHF patients.
Clinical studies with Carvedilol, an alpha-1 and non
selective b-blocker, further support the beneficial effects
of b-adrenoceptor antagonism [18,19,23,24]. Results
from the US CARVEDILOL and COPERNICUS trial, sug-
gest that prognosis in CHF may partly depend on left ven-
tricular dysfunction improvement as well as sympathetic
activity reduction [18,23]. However, additional data are
needed to define more precisely the relationships between
heart rate reduction, left ventricular function improve-
ment and survival in CHF patients. In some studies like
CIBIS II and MERIT HF, the beneficial effects of the selec-
tive b- blockers on morbidity and mortality were observed
specially in patients functional class II and III. In COPER-
NICUS a multicentric placebo controlled clinical trial
with Carvedilol, these effect was ascertained even in
patients functional class IV [23], demonstrating that
patients with CHF, independently of their functional
class, should receive b-blocker therapy.
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Current guidelines for the management of CHF strongly
recommend the use of beta-blockade in management of
CHF. However, these benefits have not been proven in
Chagas' cardiomyopathy [25,26]. Nevertheless, there are
reasons to believe that beta-blockade will be beneficial for
these patients.
First, patients with CHF due to CD have a raised end-
diastolic pressure associated with a low systemic blood
pressure, which lead to low transmyocardial pressure gra-
dient and subendocardial ischemia. Therefore, reduction
in myocardial oxygen demand due to beta-blockade could
be expected to be beneficial in this situation, even in non
ischemic CHF patients. Second the reduction in sudden
cardiac deaths and serious ventricular arrhythmias suggest
that an anti arrhythmic effect is an important component
of beta-blockade. This anti-arrhythmic effect is explicable
not only on an anti-ischemic basis but also by blockade of
sympathetic activity, which is indeed increased in patients
with Chagas' cardiomyopathy. Third, prolonged activa-
tion of the sympathetic nervous system can accelerate the
progression of heart failure, and the rate of progression
can be substantially decreased using pharmacological
agents that interfere with sympathetic activity in the heart
and peripheral blood vessels. There is clear evidence of
increased circulating beta-adrenergic antibodies in Cha-
gas' disease providing further theoretical support for the
use of beta-adrenergic blockade in this group of patients.
Beta-blockers already proven to be beneficial in CHF
patients are metoprolol, bisoprolol and carvedilol, drugs
which have been tested in over 10.000 patients in more
than 20 placebo-controlled clinical trials enrolling men
and women with systolic dysfunction due to ischemia,
hypertension and dilated idiopathic cardiomyopathy.
Bisoprolol is a beta-1 selective blocker with the highest
selectivity for this receptor, in doses less than 10 mg it has
very little or no effect on beta-2 receptors. Bisoprolol was
first tested in CHF in the CIBIS I trial which enrolled 641
patients and showed improvement in functional class,
less hospitalizations for heart failure and a trend to
improved survival. The much larger randomized CIBIS II
assigned 2647 patients with class III or IV HF and an LVEF
<40 percent to bisoprolol or placebo; the patients also
received standard therapy with diuretics and ACE inhibi-
tors. After an average follow-up of 1.4 years, the trial was
prematurely stopped when the benefits were observed in
the active treatment group: significant reduction in total
all-cause mortality (11.8 versus 17.3 percent] that was
independent of the severity or cause of HF. This benefit
was primarily due to a reduction in SCD (3.6 versus 6.3
percent, p < 0.001], with a non-significant trend toward
fewer deaths from HF; significant 15 percent reduction in
hospital admissions for any cause and a 30 percent reduc-
tion in admissions for HF (p < 0.0001). Considering all
the beneficial effects beta-blockers in patients with mild
to severe CHF due to ischemic and non ischemic disease,
there is no data regarding its potential effects in patients
with CHF due to Chagas' disease. Based on the aforemen-
tioned we propose to develop a multi-center placebo con-
trolled clinical trial to evaluate the effect of Bisoprolol in
patients with CHF due to CD.
Consquences of Chagas' disease
CD is the major cause of disability secondary to tropical
diseases in young adults from Latin America. In Colom-
bia, 18% of the population lives in CD endemic areas,
900,000 people are infected and over three million are at
high risk of being infected. The Northeastern region car-
ries the highest T. cruzi infection rate and CD prevalence.
However, the incidence of CCM among T. cruzi infected
people is unknown and the mechanisms that lead from
infection to CCM are uncertain. The mechanisms that trig-
ger the development of CCM in 20%–30% of those
infected remain a matter of debate.
Despite the high social burden of the disease no large clin-
ical trials have been performed to determine the effects of
standard heart failure therapy on hard outcomes in
patients with CCM. Experimental and clinical evidence
supports the fact that CCM may be primarily an adrener-
gic cardiomyopathy. Circulating antibodies to beta-adren-
ergic receptors have recently been described by Esterin-
Borda et al providing further support to the "adrenergic
hypothesis". A marked reduction in overall mortality and
significant improvement in quality of life, HF hospital
admissions, reduction in sudden cardiac death have been
reported by the mayor clinical trial using beta-adrenergic
blockade. The CIBIS trials using Bisoprolol have definitely
established the beneficial effects of this compound in
patients with both ischemic and non-ischemic dilated car-
diomyopathy and HF. We therefore hypothesize that
administration of Bisoprolol compared to placebo in
patients with CCC on standard HF therapy (Digoxin,
ACEi, Diuretics) will have a 30% RR in a specified prede-
termined composite outcome.
Expected impact
We expect that Bisoprolol in patients with CCM will deter-
mine a 30% relative risk reduction in mortality and mor-
bidity. In the long term, we expect that this project will
contribute to reduce the impact of the CCM and the
health burden on the Colombian's health care system,
particularly related with HF secondary to CCM.
Direct and indirect user
The direct users will be the seropositive subjects for T.
cruzi, with different NYHA functional class of heart failure
that will recieve b-blocker therapy, which may reduce the
morbidity and mortality in these patients. Other direct
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users will be all physicians in charge of managing these
patients. They may have more accurate information
regarding the current managment of Chagas' disease. The
indirect user will be the Colombian health policy devel-
opers which will be benefited by the results of this study,
in order to decrease the economic burden that CCM has
on the Colombian health care system.
Methods
Objectives
In order to achieve these objectives we defined primary
and secondary outcomes which apply to this specific car-
diomyopathy, addressing the higher incidence of ven-
tricular arrhythmias and heart block.
Primary objective
To investigate the effect of the beta-blocker bisoprolol on
survival and HF hospitalization rates, and other previ-
ously predefined outcomes in patients with Chagas' cardi-
omyopathy and heart failure.
Secondary objective
To investigate the effect of the beta-blocker bisoprolol on
quality of life, conduction disease progression and need
for electrical therapy (i.e. pacemaker, ICD, CRT).
Hypotheses
1. Bisoprolol will reduce cardiovascular death in patients
with Chagas' cardiomyopathy with heart failure func-
tional class NYHA II to IV.
2. Bisoprolol is safe in patients without advanced heart
block.
3. Bisoprolol will significantly reduce hospitalization
rates due to heart failure in patients with Chagas' cardio-
myopathy in functional class NYHA II to IV.
Study design
CHARITY is a multicenter randomized prospective, dou-
ble blind, placebo-controlled, forced-titration study in
subjects with CHF secondary to CCM.
Study development
The study will last 2 years. Patient recruitment will take 12
months with an average follow-up time of 1.5 years per
patient.
1. Months 0 to 2: Training of the Personal and techniques
standardization
2. Months 2 to 6: Patients recruitment and data recollec-
tion
3. Months 6 to 24: Follow up of patients
4. Months 24 to 30: Data analysis
Those subjects with positive serology for T. cruzy who
meet the inclusion/exclusion criteria will receive placebo
or Bisoprolol in addition to standard therapy for chronic
heart failure which includes an ACE-inhibitor and may
include diuretics or other medication such as digitalis or
nitrates for heart failure. Patients included in CHARITY
should be on stable doses of an ACE-inhibitor. Diuretics
can be added to treatment as needed but patients must be
on stable doses of each drug during four weeks prior to
randomization.
500 subjects will be randomized in two arms; one will
receive oral bisoprolol and the other placebo, during the
duration of the study. Forced titration will start with the
lowest oral dose of 2.5 mg qd and will be up-titrated in 2.5
mg increments every two weeks until the maximum toler-
ated dose is achieved or 10 mg qd is reached. In case of
intolerance, dose will be reduced to the previously toler-
ated lower dose. Subjects not tolerating the lower dose of
2.5 qd will have a treatment interruption. The best toler-
ated dose will be continued for one month, then a security
visit will re-asses tolerance. Thereafter patients will be
controlled every three months until they complete the
mean follow-up period of two years. Standard heart fail-
ure therapy with ACE-inhibitors, diurectics, digitalis and
nitrates will be strongly reinforced in both parallel arms.
Blinding
Patients and investigators will remain blinded during the
trial. The treatment codes will remain blinded until the
database is locked for final analysis.
Pretreatment considerations
Baseline vital signs will be obtained with patients in the
sitting and after 3 minutes in the standing position.
Twelve-lead ECGs will be recorded in each patient.
Left ventricular ejection fraction at rest will be determined
by echocardiography, using a modified Simpson's rule to
calculate LV volumes.
Quality of life questionnaire will be administrated two
weeks apart during baseline examination using a trans-
lated-validated version of the "Minnesota living with
heart failure" questionnaire.
Minimum of two 6-minutes corridor walk test once a
week over a 2-week period will be performed. The last
value will be used if it is within 10% of the previous value.
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Follow-up period
ECG tracings will be recorded during the security visit and
at 1 and 2 years.
Patients will be followed for two years after randomiza-
tion.
Repeat echocardiograms will be recorded at 1 and 2 years
of follow-up along with HF Quality of-life questionnaire
and six-minute walk tests.
Clinical measurements will be obtained every three
months along with an assessment of treatment adherence
and tolerance. Mortality and hospitalization events will
be ascertained by telephonic interview and verified with
hospital charts review, up to two years after randomiza-
tion.
Selection and withdrawal of subjects
Inclusion criteria
1. Males or females aged 18 to 70 years.
2. Heart failure symptoms NYHA functional class II to IV
3. Left ventricular ejection fraction <40% determined by
bi-dimensional echocardiography using modified Simp-
son's rule for ventricular volumes.
4. Subjects must be on standard and stable outpatient
doses of ACEIs or angiotensin II receptor antagonist for at
least four weeks.
5. Subjects receiving diuretics must be on a stable dose for
at least two weeks.
6. Clinical Euvolemia: as evidenced by absence of rales, no
pleural effusion or ascitis and no more than minimal
peripheral edema.
Exclusion criteria
1. CHF due to ischemic heart disease, valve disease or any
other etiology different than CD.
2. Severe aortic insufficiency
3. Baseline advanced AV block defined as Mobitz type 2 or
third degree AV block
4. Serum creatinine >2.5 mg/dl.
5. Resting Heart rate less < 45 bpm
6. Known malignancy and other severe disease which
shorten life expectancy < 6 months.
7. Subjects with contraindications for beta-blockers:
severe obstructive chronic pulmonary disease, asthma,
severe pulmonary hypertension, type 1 diabetes mellitus
or history of hypoglicemia.
8. Suspected or confirmed chronic infectious disease
including HIV and hepatitis B.
9. History of active substance or alcohol abuse within the
last year.
10. Clinically significant psychiatric illness which can neg-
atively affect the subject compliance and participation in
the trial.
11. Pregnancy or lactation.
12. Organic disease or gastrointestinal surgery which can
affect the oral absorption and pharmacodynamics of the
medication under study.
13. Enrollment and participation in other active treatment
trial within the previous month.
14. Failure to provide written informed consent.
Interruption of treatment
Trial treatment should be interrupted under the following
conditions.
1. The patient decides it is in his/her best interest.
2. The investigator considers it is advisable or in the
patient' s best interest.
3. Intolerable adverse experience(s).
4. Presence of life-threatening conditions despite adjust-
ment of therapy.
If study treatment is interrupted, every effort should be
made to reinstate treatment as soon as possible and med-
ically acceptable. The re-initiation dose is determined at
investigator' s discretion and the dose may be reduced or
re-started at the last dose level. Patients with treatment
interruption should continue on the protocol's visit
schedule and study procedures except drug dispensing.
Treatments
The FCV Research Institute (Instituto de Investigaciones
FCV) will supply ranurated 5 mg bisoprolol tablets and
matched placebo needed for the whole duration of the
trial. Study drug and placebo have been kindly provided
by Merck Colombia.
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Efficacy assessment
Efficacy assessments will be made at every visit during the
trial following randomization. Information will be
recorded in the supplied CRF formats dealing with clinical
variables, Adverse Events (AE), Serious Adverse Events
(SAE) and endpoints.
Primary outcomes
Primary outcomes are the first occurrence of any of the
following:
1. Cardiovascular death.
2. Hospital admission caused by heart failure.
3. Major adverse cardiovascular events: stroke, systemic
embolism, resuscitated sudden death.
4. Bradycardia requiring pacemaker implantation.
5. Clinically significant sustained monomorphic ventricu-
lar tachycardia causing syncope: sustained ventricular
tachycardia or ventricular fibrillation.
Each of the primary endpoints will be recorded on the SAE
form and in the individual corresponding form for each
endpoint.
Secondary efficacy outcomes
Secondary outcomes are the occurrence of any of the fol-
lowing:
1. Non-cardiovascular death.
2. Heart failure worsening or mortality related with CHF.
3. New AV block.
4. Need for Implantable cardioverter-defibrillator (ICD),
Cardiac resynchronization Therapy (CRT) or Pacemaker
therapy (PM).
5. Perceived quality of life worsening.
Endpoint definitions
1. Cardiovascular death: any death attributable to a car-
diac or vascular cause occurring within two years after ran-
domization.
2. Non-cardiovascular death: death from any cause
excluding cardiovascular diseases occurring within two
years after randomization.
3. Hospital admission/hospitalization caused by heart
failure: admission in a hospital or clinic during at least 24
hours caused by heart failure worsening. It excludes pro-
cedures and hospitalization for procedures which have
been scheduled and not due to worsening of the current
heart failure condition since randomization.
4. Heart failure worsening: decline of at least one func-
tional class as defined by the New York Heart Association
occurring during any inter- visit period of three months
needing inotropic support, IV diuretics, medication dose
adjustments or additional drugs for compensation.
5. Perceived quality of life worsening: increase in the
"Minnesota living with heart failure" test score of at least
10 points. The test' s score ranges from 0 (best) to 100
(worst).
6. New AV block: appearance of any AV conduction dis-
turbance including first, second and third degree AV block
after randomization.
7. Bradycardia requiring pacemaker implantation: ven-
tricular rates < 50 per minute due to any cause including
sick-sinus syndrome and AV block, causing symptoms or
disability and complying with current indications for per-
manent pacemaker implantation.
8. ICD: Implantable cardioverter-defibrillator indicated
for the prevention and treatment of sudden death, ven-
tricular tachycardia/ventricular fibrillation.
9. CRT: cardiac resynchronization therapy or biventricular
pacing or ventricular bifocal pacing for the treatment of
advanced heart failure.
10. PM: permanent pacemaker for the treatment of con-
duction disturbances.
11. Clinically significant ventricular arrhythmias: sus-
tained monomorphic ventricular tachycardia or ventricu-
lar fibrillation with symptoms caused by hemodynamic
or perfusion alterations, circulatory collapse or syncope.
Monitoring committees
Steering committee
The Steering Committee is composed of a group of
national leaders who will mostly be cardiologists, since
patients with CHF and Chagas' disease are most often
cared for by cardiologists. This group will be supple-
mented with experts in neurology, electrophysiology,
coagulation and thrombosis.
The committee has the overall responsibility for produc-
ing and conducting a scientifically sound design and
ensuring accurate reporting of the study. In that capacity,
the Steering Committee must address and resolve scien-
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tific issues encountered during the study. This committee
will meet at least twice a year. The main role of the Steer-
ing Committee is the development of the protocol and
CRF and to ensure appropriate conduction of the trial. The
steering committee is composed by the principal investi-
gators and site investigators. The chairman of the steering
committee is the principal investigator. All proposed
ancillary research investigations on patients enrolled in
CHARITY must be approved by the Steering Committee.
The primary scientific publication reporting the study
results is the responsibility of the Steering Committee.
Collaborating Investigators or members of the various
study committees wishing to prepare secondary publica-
tions must submit proposals and manuscripts to the Steer-
ing Committee for approval. The final decision on the
contents of all publications will be the responsibility of
the CHARITY Operations Committee.
CHARITY Operations Committee
The Operations Committee will consist of a select group
of Steering Committee members chosen for their specific
expertise and experience. This group will be responsible
for ensuring that study execution and management are of
the highest quality. The Operations Committee will con-
vene regularly by teleconference and/or face-to-face meet-
ing (at least every 2 months) to discuss and report on the
ongoing supervision of the study. Issues relating to regu-
latory reporting are the responsibility of the Sponsor,
although the Operations Committee is to be kept
informed of these activities. The Operations Committee
will determine its own guidelines and approve the criteria
and guidelines of the other committees prior to com-
mencement of the study. The Operations Committee will
need to determine its own working guidelines, especially
regarding the decision-making process on specific aspects
of the study conduct. Throughout the trial, the Operations
Committee will monitor the overall number of confirmed
primary events and may decide to increase the sample size
in order to maintain or enhance the statistical power of
the study.
FCVRI project office
The FCVRI Project Office is located at the Instituto de
Investigaciones/FCV in Bucaramanga, Santander, Colom-
bia. The FCVRI Project Office is independent and its pri-
mary function is to facilitate and oversee the execution of
the study. The FCV Project Office will keep the Operations
Committee appraised of the progress and conduct of the
trial and will provide ongoing administrative and meth-
odological support to the Event Adjudication Committee
and the DSMB. It will also make available appropriate
study data and/or documentation to these committees.
Oversight activities of the FCCVProject Office include the
following :
1. Develop and manage the Central Study Database, per-
form data entry and validate records in the DataFax sys-
tem:
2. Implement and manage the central randomization sys-
tem;
3. Generate patient visit schedules for all centres;
4. Compile and generate monthly study status reports for
general distribution to all personnel involved in the study,
centrally and locally;
5. Maintain necessary communication with all National
Investigators and study personnel in order to provide
methodological and administrative assistance to them, so
that the requirements of a well-disciplined and successful
trial can be fulfilled;
6. Provide appropriate reports every two weeks in order to
facilitate and optimize site monitoring and study drug dis-
tribution;
7. Perform the final analysis for scientific publication.
The FCVRI Project Office will also collaborate in the fol-
lowing areas:
1. Ensure protocol adherence;
2. Assess timely completion and submission of Case
Report Forms (CRFs) and support documents;
3. Monitor quality and homogeneity of all data processing
activities;
4. implement appropriate measures for data quality con-
trol.
As part of the overall study management, the FCVRI
Project Office will prepare and distribute monthly status
reports to all collaborators at the central and local level,
including investigators. The primary purpose of these
reports will be to keep all Investigators informed of the
performance at their Clinical Centre in relation to the
combined performance of the other participating Clinical
Centres. These reports will contain the following informa-
tion:
1. Patient accrual rates
2. Permanent study drug discontinuations
3. Overdue clinical assessments
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4. Projected patient follow-up schedules
Data and Safety Monitoring Board (DSMB)
CHARITY will be conducted in a double-blind manner in
which patients and treating physicians are blinded. The
trial management team (Operations Committee, Event
Adjudication Committee, and the FCVRI Project Office)
will also be blinded with respect to treatment allocation.
The DSMB will include at least 2 prominent cardiologists
and a neurologist, as well as a statistician. Their mandate
will be to provide on-going review of the safety of all the
investigational treatments. To facilitate its responsibili-
ties, the DSMB will have an Associated Statistician who
will receive study data directly from the Central Study
Database and who will remain independent of the trial
management team. The DSMB Associated Statistician is
not a member of the DSMB, but presents data to the com-
mittee and is responsible to the Chairman. The DSMB
Associated Statistician, being unblinded, will not be able
to edit/alter any part of the Central Study Database. Rou-
tine access to the treatment code will be restricted to the
Chairman of the DSMB, except for emergency unblinding
on a case by case basis.
DSMB responsibilities
Primary
1. Regular (at least every 3 months) review of safety data
and serious adverse events
2. Formal interim analyses of efficacy data
3. Feedback to the Operations Committee
Secondary
1. Respond to special requests from regulatory authorities
or IRBs
2. Recommendations for protocol amendments
3. Verification of final analysis of the study will be done
by the DSMB Associated Statistician
Recommendation to stop a trial early for safety reasons is,
by definition, a qualitative judgment. The DSMB is com-
posed of eminent clinicians and methodologists who are
experienced with clinical trials and can be relied upon to
exercise good judgment in weighing the potential risks
and benefits to patients as data accumulate in this trial.
Safety aspects and more specifically severe bradycardia,
heart block, severe hypotension will be monitored. No
formal boundaries will be proposed, but clear, consistent,
and persistent evidence of net harm that overwhelms any
benefit should be apparent. A recommendation to stop
the trial will be based on the pattern of treatment effect
across all endpoints, as well as the benefit/risk ratio.
The DSMB will fulfill its responsibility to monitor the
safety of patients in CHARITY by conducting formal
reviews of accumulated safety and efficacy data. These
reviews will normally occur at regular intervals. The
DSMB Associated Statistician will prepare a report of
aggregate data summaries and individual patient data list-
ings, where appropriate, for each treatment group. This
report will be circulated to each member of the DSMB at
least one week prior to their collective review. The com-
mittee will then convene, either by face-to-face meeting or
by telephone conference call, to make its recommenda-
tion to the Operations Committee with respect to contin-
uance of the trial. A formal written communication to the
Chairman of the Operations Committee will then follow.
Minutes of all official meetings of the DSMB will ulti-
mately be part of the Sponsor's master files (archives). The
report of data summaries and listings will include infor-
mation on both safety and efficacy parameters, together
with status reports designed to show the extent to which
the trial is being executed according to protocol. Included
among the safety data will be (a) all deaths and (b)
adverse events. Efficacy summaries will provide informa-
tion on the occurrence of study outcomes. The outcome
events are considered as distinct from adverse events and
summarized separately. At each review by the DSMB, con-
sideration of a decision to stop the trial on grounds of
patient safety will weigh the current evidence of differ-
ences between treatments regarding adverse effects (as
expressed by mortality, adverse event reports, etc.) against
emerging trends in efficacy. Providing efficacy data at each
of these routine safety reviews does not constitute a for-
mal interim analysis of efficacy. Blinded data for the safety
review will be made available from the Central Study
Database. Serious adverse events are required to be
reported rapidly to the FCVRI Project Office and will be
entered into a separate data base. These reports will be
added to the data to be reviewed by the DSMB. Outcome
events will be reviewed by the Event Adjudication Com-
mittee on an ongoing basis to determine if each reported
event meets the defined criteria for a study outcome event.
The DSMB will review data on all reported outcome
events. Additional summaries will show the results of the
Event Adjudication Committee's judgements on the sub-
set of reports that has been reviewed by this committee.
This committee is independent from the FCVRI and its
responsibilities are to review the protocol and perform an
interim analysis plan, review safety, efficacy, compliance
and trial progress at 12 months after the first randomiza-
tion and if requested by the Steering Committee. The Data
and Safety Monitoring Board (DSMB) will make recom-
mendations to the Steering Committee about any poten-
tial problems. Any major recommendation, e.g.
amending the protocol or stopping the trial will be
reviewed and ratified by the Steering Committee.
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Adverse Events and Adjudication Committee
The Event Adjudication Committee is charged with the
responsibility for validating all reported primary fatal and
nonfatal outcomes and validating the classification of
cause of death. The Event Adjudication process will be
coordinated at the FCVRI Project Office in Bucaramanga.
This committee, composed of experts in the field will
review, in a blinded manner; all reported outcome events
to provide consistency and validity in the assessment of
outcomes. Their decisions will be based on blind clinical
data provided and they will consider the impressions of
the clinical investigator. Their decisions will be used in the
final analysis. Members of the Event Adjudication Com-
mittee will be chosen based on their clinical expertise.
Adjudicators will be trained at a preliminary meeting
where study definitions will be reviewed and test cases
performed to ensure uniform application of study defini-
tions. Reported events will be adjudicated by at least one
committee member. Dossiers of reported events will be
prepared and distributed to committee members on a reg-
ular basis to ensure that events are adjudicated in a timely
fashion. Each committee member will be requested to
review the dossiers and acknowledge in writing their
agreement/disagreement with the investigator's interpre-
tation of events.
The AE Committee (AE&AC) is composed by clinical
experts and one principal investigator, its responsibilities
are to review and verify every AE, SAE and Adverse Drug
Reactions (ADR) reported, and to supervise all relevant
SAE information is complete. The AE&EC will validate all
SAE in a blinded form and notify investigators, Independ-
ent Ethics Committees and regulation authorities of all
SAE and clinically relevant AE. The AE&EC will also vali-
date outcomes providing standard classifications and def-
initions and reviewing supporting information provided
by investigators.
Safety assessment
Safety assessment will consist of monitorization of all
adverse events, serious adverse events and protocol out-
comes. Physical exam including sitting and standing
blood pressures, heart rate and presence of CHF signs will
be measured and recorded in the case report form (CRF).
During visit 4, the security visit, an ECG will be recorded
to assess heart rate and presence of conduction distur-
bances before proceeding to dispense medication.
Adverse events
All adverse events informed by the subjects, detected by
the investigators or detected through physical examina-
tion will be recorded in the individual' s CRF and reported
to the principal investigators within the next five days.
An adverse Event (AE) is any untoward or undesirable
medical occurrence in a subject that does not necessarily
have a causal relationship with the study treatment medi-
cation. An AE can be any symptom, sign or medical con-
dition occurring after starting the study drug whether it
corresponds to bisoprolol or placebo. Medical conditions
present before starting the study are considered AE only if
they worsen after starting the study treatment. An abnor-
mal laboratory finding not present before starting the
study treatment is also considered an AE and should be
recorded in the CRF.
The Adverse Events is described in the CRF Adverse Events
form (CRF 50) including date and duration, severity
(mild, moderate, severe, only laboratory abnormality),
relation with the study drug (suspected, not suspected),
action taken (none, drug discontinued, dose adjustment,
drug interruption, hospitalization, withdrawal) and out-
come of the event (recovery, persistent problem, sequelae,
death). All fields requested in the AE form must be filled
and submitted to the AE committee.
Effects of Bisoprolol
The known effects and tolerability to bisoprolol will be
monitored in each visit; any intolerability or negative
change in vital signs will be recorded as an AE. The follow-
ing definitions apply to the side effects associated with
Bisoprolol independent of the study' s endpoints.
1. Bradycardia: Bradycardia is defined as a frequency of
<45 beats per minute detected by pulse palpation, cardiac
auscultation or ventricular frequency in an ECG.
2. Hypotension: Hypotension is defined as a sitting systo-
lic blood pressure < 100 mmHg or a sitting diastolic blood
pressure < 60 mmHg. The investigator must sate whether
hypotension is asymptomatic or symptomatic.
3. Orthostatic hypotension: Orthostatic hypotension is a
decrease in systolic or diastolic blood pressure of ≥20
mmHg or ≥10 mmHg respectively. The investigator must
sate whether orthostatic hypotension is asymptomatic or
symptomatic.
4. Fatigue: Fatigue is described as a perceived sensation of
weakness during ordinary physical activities not present
before starting the study treatment drug.
5. Bronchospasm: Bronchospasm is defined as bronchial
wheezing during auscultation or wheezing perceived by
the subject during respiratory symptoms of cough or dys-
pnea.
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6. Cold extremities: Cold extremities are defined as the
sensation of coldness in digits, hands or feet not present
before starting the study drug.
Serious Adverse Events
Serious Adverse Event (SAE) is any untoward medical
occurrence that at any dose of the study drug results in:
1. Death
2. Is life-threatening
3. Requires hospitalization or prolongation of existing
hospitalization
4. Results in persistent or significant disability
5. Results in congenital anomaly at birth
SAE will be recorded in the CRF SAE form and reported to
the principal investigator at FCV within 24 hours of learn-
ing of its occurrence. The SAE form requires information
about date, medical diagnosis, consequences and severity
(fatal, life-threatening, requiring hospitalization, disabil-
ity/incapacity, birth defects or other consequence), date of
hospitalization, date of death, study treatment drug dose,
date of first dose, date of dose adjustment, relationship
with the study treatment drug (suspected, not suspected)
and study withdrawal of the subject (yes or no). The SAE
form must be signed by the principal investigator and the
study monitor.
All SAE will be followed until their resolution or the com-
pletion of the trial. Follow-up will be recorded in the CRF
SAE follow-up (CRF52) form stating the subject' s out-
come as resolved, dead, lost to follow-up or unknown.
Hospitalization SAE should include copy of the summary
epicrisis from the corresponding hospital or clinic. All SAE
follow-up forms must be signed by the principal investi-
gator and the study monitor.
SAE which constitute endpoint according to the protocol'
s definitions, will be recorded additionally in the CRF cor-
responding endpoint form. Each endpoint has its own
CRF page which must be submitted to the AE committee
for validation.
Events not considered SAE are hospitalization for:
1. Routine treatment or pre-scheduled hospitalizations for
heart failure not associated with any clinical deterioration.
2. Elective or scheduled treatment for pre-existing condi-
tions that did not worsen during the study.
Statistical methods
Descriptive statistical analysis will be composed with sim-
ple distribution of frequencies, calculation of propor-
tions, means, their respective standard deviations and
95% confidence intervals. For effects of group compari-
son, t-test and Mann-Whitney tests will be used according
to the dependent variable distribution. For categoric vari-
ables, the Chi-square test or the exact Fisher test will be
applied as corresponding. Patient survival and hospitali-
zation rates will be described using Kaplan-Meijer esti-
mates and survival graphs. Cox regression will be used for
the multivariate analysis of time to death and time to hos-
pitalization. Formal efficacy interim analyses will take
place one year after the recruitment phase.
Ethical aspects
This study will be conducted in accordance with the Dec-
laration of Helsinki and with the Colombian legislation
as per the Resolution 8430/93 from the Ministry of
Health. Prior to the admission of the patients in the study,
the objectives and the methodology will be explained and
the informed consent obtained. The study was approved
by the Research Ethic Committee of the Cardiovascular
Foundation of Colombia (No. 059/June 29/2003). The
right to confidentiality of the patients will be maintained
in all the phases of the study.
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